Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Language
Publication year range
3.
Oral Maxillofac Surg Clin North Am ; 34(2): 213-220, 2022 May.
Article in English | MEDLINE | ID: mdl-35491078

ABSTRACT

Melanoma is often initially evaluated by the dermatologist. A methodical evaluation requires complete history and detailed clinical physical examination and appropriate decisions regarding biopsies. Accurate diagnosis and staging require clinicopathologic correlation and an excellent relationship with the dermatopathologist. Subsequent definitive treatment may be managed entirely by the dermatologist or might require a multidisciplinary team of specialists.


Subject(s)
Head and Neck Neoplasms , Melanoma , Dermatologists , Head , Head and Neck Neoplasms/diagnosis , Head and Neck Neoplasms/surgery , Humans , Melanoma/diagnosis , Melanoma/surgery , Neck
5.
Nutrients ; 9(5)2017 May 21.
Article in English | MEDLINE | ID: mdl-28531130

ABSTRACT

Non-replicating vaccines, such as those based on recombinant proteins, require adjuvants and delivery systems, which have thus far depended on mimicking pathogen danger signals and strong pro-inflammatory responses. In search of a safer and more efficacious alternative, we tested whether vaccinations with influenza recombinant hemagglutinin (HA) mixed with a novel vegetable oil in water emulsion adjuvant (Natural Immune-enhancing Delivery System, NIDS), based on the immune-enhancing synergy of vitamins A and E and a catechin, could protect against intra-nasal challenge with live influenza virus. Vaccinations of inbred Brag Albino strain c (BALB/c) mice, with HA mixed with NIDS compared to other adjuvants, i.e., a squalene oil in water emulsion (Sq. oil), and the Toll Like Receptor 3 (TLR3) agonist Poly (I:C), induced significantly lower select innate pro-inflammatory responses in serum, but induced significantly higher adaptive antibody and splenic T Helper 1 (TH1) or TH2, but not TH17, responses. Vaccinations with NIDS protected against infection, as measured by clinical scores, lung viral loads, and serum hemagglutination inhibition titers. The NIDS exhibited a strong dose sparing effect and the adjuvant action of NIDS was intact in the outbred CD1 mice. Importantly, vaccinations with the Sq. oil, but not NIDS, induced a significantly higher Serum Amyloid P component, an acute phase reactant secreted by hepatocytes, and total serum IgE. Thus, the NIDS may be used as a clinically safer and more efficacious vaccine adjuvant against influenza, and potentially other infectious diseases.


Subject(s)
Adjuvants, Immunologic/chemistry , Catechin/chemistry , Influenza Vaccines/immunology , Orthomyxoviridae Infections/prevention & control , Vitamin A/chemistry , Vitamin E/chemistry , Adjuvants, Immunologic/administration & dosage , Animals , Antibodies, Viral/blood , Catechin/administration & dosage , Immunization Schedule , Influenza Vaccines/chemistry , Mice , Orthomyxoviridae Infections/blood , Vaccines , Viral Load , Vitamin A/administration & dosage , Vitamin E/administration & dosage
SELECTION OF CITATIONS
SEARCH DETAIL
...